Glucotrack insider adds shares and receives 4,055 options expiring 2035

Rhea-AI Filing Summary

Glucotrack, Inc. director Luis Malave reported multiple stock option and common stock acquisition transactions across 2025 that increase his direct ownership. The filing shows three non‑derivative common stock acquisitions: 35 shares on 03/25/2025, 1,200 shares on 07/11/2025, and 463 shares on 10/03/2025, bringing his total direct common shares to 4,058. The filing also records a derivative transaction on 10/03/2025 for a stock option exercisable at $7.4 covering 4,055 underlying shares that expire on 10/03/2035, leaving 4,055 options held directly.

The reported grants vest monthly over 12 months starting each July 1, subject to continued service. The filing notes multiple reverse stock splits in 2024 and 2025 and states all figures reflect those splits. The report was signed by an attorney‑in‑fact on 10/07/2025.

Positive

• Director ownership increased to 4,058 shares, aligning interests with shareholders
• Large option position (4,055 options) vests monthly over 12 months, supporting retention
• Options are long‑dated (expiring 10/03/2035), giving time for value realization

Negative

• Exercise price of $7.4 may be above market at some dates (market price not provided)
• Multiple reverse stock splits (1‑for‑5; 1‑for‑20; 1‑for‑60) complicate historical share comparisons

Insights

Corporate Governance Analyst

Director received layered equity grants and exercised standard vesting terms.

The reporting shows a combination of small direct stock acquisitions and a sizeable option position: 4,055 options exercisable at $7.4 through 10/03/2035, and total direct common shares of 4,058. The option grant's vesting schedule begins each July 1 and vests in 12 monthly installments, tying economic gain to ongoing service.

Key dependencies include continued service through vesting dates and the impact of the documented reverse stock splits (1‑for‑5, 1‑for‑20, 1‑for‑60) on share counts. Watch near‑term vesting milestones through the next 12 months and the option exercise price relative to market price when available.

Equity Compensation Specialist

Vesting structure and long‑dated option provide delayed dilution and retention incentives.

The option is long‑dated (expires 10/03/2035) with a fixed exercise price of $7.4, and the disclosed monthly vesting over 12 months aligns compensation with continued service rather than immediate liquidity. The direct acquisitions are small on their own but increase the director's outright stake to 4,058 shares.

Material near‑term items to monitor are the monthly vesting schedule starting each July 1 and any future disclosures about option exercises or additional grants that would affect outstanding share counts and potential dilution within the next 12 months.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Malave Luis

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	4,055	$0.00	--
Grant/Award	Common Stock, par value $0.001 per share	463	$0.00	--
Grant/Award	Common Stock, par value $0.001 per share	1,200	$0.00	--
Grant/Award	Common Stock, par value $0.001 per share	35	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 4,055 shares (Direct); Common Stock, par value $0.001 per share — 4,058 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malave Luis

(Last) (First) (Middle)

C/O GLUCOTRACK, INC.

301 RTE. 17 NORTH, SUITE 800

(Street)

RUTHERFORD NJ 07070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Glucotrack, Inc. [ GCTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001 per share	03/25/2025		A		35	A	$0	2,395	D
Common Stock, par value $0.001 per share	07/11/2025		A		1,200	A	$0	3,595	D
Common Stock, par value $0.001 per share	10/03/2025		A		463	A	$0	4,058	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$7.4	10/03/2025		A		4,055		(1)	10/03/2035	Common Stock, par value $0.001 per share	4,055	$0	4,055	D

Explanation of Responses:

1. Each option grant has a vesting commencement date of July 1 of the applicable calendar year and vests in 12 equal monthly installments over the 12-month period ending June 30 of the following year, subject to the reporting person's continued service to the Issuer through each vesting date.

Remarks:

On May 17, 2024, a 1-for-5 reverse stock split of the Issuer's common stock, par value $0.001 per share (the "Common Stock") was implemented (the "2024 Reverse Split"). On February 25, 2025, a 1-for-20 reverse stock split of the Common Stock was implemented (the "February 2025 Reverse Split"), and on June 13, 2025, a 1-for-60 reverse stock split of the Common Stock was implemented (the "June 2025 Reverse Stock Split", and together with the 2024 Reverse Split and the February 2025 Reverse Stock Split, the "Reverse Stock Splits"). All figures presented in this Form 4 reflect the Reverse Stock Splits.

	/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Glucotrack (GCTK) director Luis Malave report?

He reported three common stock acquisitions totaling 698 shares in 2025 dates (03/25/2025, 07/11/2025, 10/03/2025) and a derivative transaction granting 4,055 stock options exercisable at $7.4.

How many total common shares does Luis Malave beneficially own after the reported transactions?

The filing shows a direct beneficial ownership of 4,058 common shares following the reported transactions.

What are the key terms of the reported stock option for GCTK?

The option covers 4,055 underlying shares, has an exercise price of $7.4, vests monthly over 12 months beginning each July 1, and expires on 10/03/2035.

Do the reported numbers account for recent reverse stock splits?

Yes. The filing states all figures reflect a 1‑for‑5 reverse split in 2024, a 1‑for‑20 reverse split on 02/25/2025, and a 1‑for‑60 reverse split on 06/13/2025.

When was this Form 4 signed and filed?

The signature by the attorney‑in‑fact is dated 10/07/2025.